Vertex Pharmaceuticals | LinkedIn (original) (raw)

``

About us

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and have made significant advancements in multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continue to progress clinical and research programs in these diseases. We also have a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where we have deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Our global HQ is in Boston, and we have research and development (R&D) sites and commercial offices worldwide. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. We have also earned a spot on TIME Most Influential Companies, TIME Best Inventions, and Fast Company Most Innovative Companies lists. Our research and medicines have received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the Prix Galien, the Scrip Award and the Breakthrough Prize awards. Read our community guidelines: https://www.vrtx.com/vertexs-community-guidelines/

Industry

Biotechnology Research

Company size

5,001-10,000 employees

Headquarters

Boston, MA

Type

Public Company

Founded

1989

Specialties

cystic fibrosis, alpha-1 antitrypsin deficiency (AATD), APOL1-mediated kidney diseases, sickle cell disease, beta thalassemia, Duchenne muscular dystrophy, and type 1 diabetes mellitus

Locations

Employees at Vertex Pharmaceuticals

Updates

Join now to see what you are missing

Join now

Similar pages

Browse jobs

Stock

VRTX

January 23, 2025

NASDAQ

20 minutes delay

Open

429.25

Low

429.25

High

430.54

Data from Refinitiv

See more info on Bing

Funding